ATE335073T1 - Replikationsprozess des hepatitis c virus - Google Patents

Replikationsprozess des hepatitis c virus

Info

Publication number
ATE335073T1
ATE335073T1 AT02727692T AT02727692T ATE335073T1 AT E335073 T1 ATE335073 T1 AT E335073T1 AT 02727692 T AT02727692 T AT 02727692T AT 02727692 T AT02727692 T AT 02727692T AT E335073 T1 ATE335073 T1 AT E335073T1
Authority
AT
Austria
Prior art keywords
hcv
cells
nucleic acid
structural proteins
synthesis
Prior art date
Application number
AT02727692T
Other languages
English (en)
Inventor
Czeslaw Wychowski
Gilles Duverlie
Jean Dubuisson
Andre Pillez
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE335073T1 publication Critical patent/ATE335073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02727692T 2001-04-27 2002-04-25 Replikationsprozess des hepatitis c virus ATE335073T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105732A FR2824072B1 (fr) 2001-04-27 2001-04-27 Procede de replication et de production du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
ATE335073T1 true ATE335073T1 (de) 2006-08-15

Family

ID=8862798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727692T ATE335073T1 (de) 2001-04-27 2002-04-25 Replikationsprozess des hepatitis c virus

Country Status (12)

Country Link
US (3) US7314710B2 (de)
EP (1) EP1381675B1 (de)
JP (1) JP2004527252A (de)
AT (1) ATE335073T1 (de)
AU (1) AU2002257890B2 (de)
CA (1) CA2445596A1 (de)
DE (1) DE60213578T2 (de)
ES (1) ES2269684T3 (de)
FR (1) FR2824072B1 (de)
MX (1) MXPA03009736A (de)
NZ (1) NZ529037A (de)
WO (1) WO2002088338A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
US7223787B2 (en) * 2003-10-21 2007-05-29 Board Of Regents, The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication
EP1801116A1 (de) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV-Replikon-Shuttlevektoren
AU2008262333B2 (en) 2007-06-08 2014-07-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US10590391B2 (en) 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
GB0718446D0 (en) * 2007-09-21 2007-10-31 Prendergast Patrick T Compositions and methods for the treatment of infection
WO2010057015A1 (en) 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
US20100173281A1 (en) * 2009-01-06 2010-07-08 Roche Palo Alto Llc HCV NS3 protease replicon shuttle vectors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
AU6943994A (en) * 1993-05-04 1994-11-21 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis c virus cell propagation and related methods
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
WO1996024662A1 (en) * 1995-02-10 1996-08-15 Consiglio Nazionale Delle Ricerche Process to 'in vitro' propagate the hepatitis c virus (hcv) in non lymphoblastoid animal cell cultures and products thereof
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US6808876B1 (en) * 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
WO2002038793A2 (en) * 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c

Also Published As

Publication number Publication date
US7314710B2 (en) 2008-01-01
FR2824072A1 (fr) 2002-10-31
US20100159467A1 (en) 2010-06-24
US7655406B2 (en) 2010-02-02
AU2002257890B2 (en) 2008-05-22
DE60213578D1 (de) 2006-09-14
CA2445596A1 (fr) 2002-11-07
JP2004527252A (ja) 2004-09-09
NZ529037A (en) 2006-05-26
WO2002088338A3 (fr) 2003-04-03
FR2824072B1 (fr) 2004-03-12
EP1381675A2 (de) 2004-01-21
ES2269684T3 (es) 2007-04-01
US20080220410A1 (en) 2008-09-11
US20040142320A1 (en) 2004-07-22
EP1381675B1 (de) 2006-08-02
DE60213578T2 (de) 2007-08-09
MXPA03009736A (es) 2005-03-07
WO2002088338A2 (fr) 2002-11-07

Similar Documents

Publication Publication Date Title
Luo et al. Role of the 5′-proximal stem-loop structure of the 5′ untranslated region in replication and translation of hepatitis C virus RNA
Borman et al. Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro
Sizova et al. Specific interaction of eukaryotic translation initiation factor 3 with the 5′ nontranslated regions of hepatitis C virus and classical swine fever virus RNAs
Barton et al. 5′ cloverleaf in poliovirus RNA is a cis‐acting replication element required for negative‐strand synthesis
Wilson et al. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region
You et al. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication
Gamarnik et al. Interactions of viral protein 3CD and poly (rC) binding protein with the 5′ untranslated region of the poliovirus genome
Bailey et al. Structure of the 5′ nontranslated region of the coxsackievirus b3 genome: chemical modification and comparative sequence analysis
Beard et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus
Guo et al. Effect of alpha interferon on the hepatitis C virus replicon
Sun et al. De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase
Yanagi et al. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee
Tuplin et al. Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus
Behrens et al. Characterization of an autonomous subgenomic pestivirus RNA replicon
Lee et al. cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome
Song et al. Dengue and Zika virus 5′ untranslated regions harbor internal ribosomal entry site functions
Jackson et al. Internal initiation of translation of picornavirus RNAs
Laporte et al. Comparative analysis of translation efficiencies of hepatitis C virus 5′ untranslated regions among intraindividual quasispecies present in chronic infection: opposite behaviors depending on cell type
Murray et al. Persistent replication of hepatitis C virus replicons expressing the β-lactamase reporter in subpopulations of highly permissive Huh7 cells
Han et al. Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites
Zhao et al. Genetic analysis of a poliovirus/hepatitis C virus chimera: new structure for domain II of the internal ribosomal entry site of hepatitis C virus
NZ597400A (en) Methods and Materials Using Signaling Probes
DE60333042D1 (de) Eine aus dem genom von hepatitis-c-virus (hcv) genotyp 2a stammende nukleinsäure enthaltendes nukleinsäurekonstrukt und zelle mit dem dahinein transferierten nukleinsäurekonstrukt
Steil et al. Poly (A) at the 3′ end of positive-strand RNA and VPg-linked poly (U) at the 5′ end of negative-strand RNA are reciprocal templates during replication of poliovirus RNA
WO2006038129A3 (en) Hepatitis c virus replication system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties